Roche Holding AG (ROP.SW)
Swiss · CHF · Healthcare · Drug Manufacturers - General
CHF 396.50 (+1.43%) as of
Key statistics
- Market cap
- 315.92B
- P/E (TTM)
- 25.86
- Forward P/E
- 17.93
- EPS (TTM)
- 15.33
- Dividend yield
- 2.51%
- 52-week range
- 258.20 – 398.20
- Beta
- 0.33
- Revenue (TTM)
- 62.96B
- Profit margin
- 19.60%
- Analyst target
- CHF 386.36
- Volume
- 1.35M
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Basel, Switzerland
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.